Impact of paroxetine on sleep problems in 426 cancer patients receiving chemotherapy: A trial from the University of Rochester Cancer Center Community Clinical Oncology Program

Sleep Medicine

Volumn 13, Issue 9, 2012, Pages 1184-1190

  Palesh, Oxana G ^a   Mustian, Karen M ^b   Peppone, Luke J ^b   Janelsins, Michelle ^b   Sprod, Lisa K ^b   Kesler, Shelli ^a   Innominato, Pasquale F ^c,f,g   Roth, Thomas ^d   Manber, Rachel ^e   Heckler, Charles ^b   Fiscella, Kevin ^b   Morrow, Gary R ^b  

^a STANFORD CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c HÔPITAL PAUL BROUSSE   (France)

^d HENRY FORD HOSPITAL   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INSERM   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CIRCADIAN RHYTHM; DEPRESSION; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DRUG EFFICACY; FATIGUE; FEMALE; GYNECOLOGIC CANCER; HAMILTON SCALE; HEMATOLOGIC MALIGNANCY; HUMAN; INFLAMMATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; SLEEP DISORDER; SLEEP WAKING CYCLE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; SLEEP DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867463865     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2012.06.001     Document Type: Article

References (47)

1. Parker K.P., Bliwise D.L., Ribeiro M., et al. Sleep/wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. J Clin Oncol 2008, 26:2464-2472.
2. Esther Kim J.E., Dodd M.J., Aouizerat B.E., Jahan T., Miaskowski C. A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Symptom Manage 2009, 37:715-736.
3. Ancoli-Israel S., Liu L., Marler M.R., et al. Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 2006, 14:201-209.
4. Savard J., Morin C.M. Insomnia in the context of cancer: A review of a neglected problem. J Clin Oncol 2001, 19:895-908.
5. Byar K.L., Berger A.M., Bakken S.L., Cetak M.A. Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. Oncol Nurs Forum 2006, 33:E18-E26.
6. Bower J.E. Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol 2008, 26:768-777. [Review].
7. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007, 3:S7-10.
8. Balter M.B., Uhlenhuth E.H. New epidemiologic findings about insomnia and its treatment. J Clin Psychiatry 1992, 53(Suppl.):34-39.
9. Simon G.E., VonKorff M. Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 1997, 154:1417-1423.
10. Redwine L., Hauger R.L., Gillin J.C., Irwin M. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J Clin Endocrinol Metab 2000, 85:3597-3603.
11. Vgontzas A.N., Zoumakis M., Bixler E.O., et al. Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: physiologic and therapeutic implications. J Clin Endocrinol Metab 2003, 88:2087-2095.
12. Vgontzas A.N., Vhrousos G.P. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: Multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin North Am 2002, 31:15-36.
13. Meier-Ewert H.K., Ridker P.M., Rifai N., et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 2004, 43:678-683.
14. Cover H., Irwin M. Immunity and depression: insomnia, retardation, and reduction of natural killer cell activity. J Behav Med 1994, 17:217-223.
15. Savard J., Miller S.M., Mills M., et al. Association between subjective sleep quality and depression on immunocompetence in low-income women at risk for cervical cancer. Psychosom Med 1999, 61:496-507.
16. Palesh O.G., Roscoe J.A., Mustian K.M., et al. Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. J Clin Oncol 2010, 28:292-298.
17. Savard J., Simard S., Blanchet J., Ivers H., Morin C.M. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep 2001, 24:583-590.
18. Liu L., Fiorentino L., Natarajan L., et al. Pre-treatment symptom cluster in breast cancer patients is associated with worse sleep, fatigue and depression during chemotherapy. Psychooncology. 2009, 18:187-194.
19. Andrykowski M.A., Curran S.L., Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J Behav Med 1998, 21:1-18.
20. Stepanski E.J., Walker M.S., Schwartzberg L.S., Blakely L.J., Ong J.C., Houts A.C. The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. J Clin Sleep Med 2009, 5(2):132-136.
21. Redeker N.S., Lev E.L., Ruggiero J. Insomnia, fatigue, anxiety, depression, and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract 2000, 14:275-290.
22. Spiegel D., Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry 2003, 54:269-282.
23. Chida Y., Hamer M., Wardle J., Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival?. Nat Clin Pract Oncol 2008, 5:466-475.
24. Spiegel D., Sephton S. Re: Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2002, 94:530-533.
25. Antoni M.H., Lutgendorf S.K., Cole S.W., et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 2006, 6:240-248.
26. Perlis M.L., Smith L.J., Lyness J.M., et al. Insomnia as a risk factor for onset of depression in the elderly. Behav Sleep Med 2006, 4:104-113.
27. Van Moffaert M.M. Sleep disorders and depression: the 'chicken and egg' situation. J Psychosom Res 1994, 38(Suppl. 1):9-13.
28. Mayers A.G., Baldwin D.S. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005, 20:533-559.
29. Serretti A., Cusin C., Benedetti F., et al. Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005, 137B:36-39.
30. Morrow G.R., Hickok J.T., Roscoe J.A., et al. Differential effects of paroxetine on fatigue and depression: A randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003, 21:4635-4641.
31. Roscoe J.A., Morrow G.R., Hickok J.T., et al. Effect of paroxetine hydrochloride (Paxil(R)) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005, 89:243-249.
32. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
33. Radloff L. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1977, 1:385-401.
34. Turk D.C., Okifuji A. Detecting depression in chronic pain patients. Adequacy of self- reports. Behav Res Ther 1994, 32(1):9-16.
35. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-748.
36. Breslow N.E., Day N.E. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ 1980, 5-338.
37. Blier P., De M.C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 1994, 15:220-226.
38. Dunbar G.C., Claghorn J.L., Kiev A., Rickels K., Smith W.T. A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr Scand 1993, 87:302-305.
39. Hofman M., Ryan J.L., Figueroa-Moseley C.D., Jean-Pierre P., Morrow G.R. Cancer-related fatigue: The scale of the problem. Oncologist 2007, 12(Suppl. 1):4-10.
40. Kelly C.M., Juurlink D.N., Gomes T., et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010, 340:c693.
41. Stearns V., Johnson M.D., Rae J.M., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95:1758-1764.
42. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97:30-39.
43. Morin C.M. Combined therapeutics for insomnia: should our first approach be behavioral or pharmacological?. Sleep Med 2006, 7(Suppl. 1):S15-S19.
44. Morin C.M., Hauri P.J., Espie C.A., Spielman A.J., Buysse D.J., Bootzin R.R. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep 1999, 22:1134-1156.
45. Morin C.M., Vallieres A., Guay B., et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA 2009, 301:2005-2015.
46. Berger A.M., Kuhn B.R., Farr L.A., et al. One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. J Clin Oncol 2009, 27:6033-6040.
47. Savard J., Simard S., Ivers H., Morin C.M. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. J Clin Oncol 2005, 23(25):6083-6096.